Asymmetrex’s introduction of online calculators for therapeutic stem cell dosage determination heralded as a reform of stem cell science and medicine
…the introduction of online rapid stem cell count calculators is the beginning of a reform of stem cell science and medicine.
September 13, 2022
In 2020, when Asymmetrex® first published the seminal report of its innovation for counting therapeutic tissue stem cells, the company’s president and CEO, James L. Sherley, MD, Ph.D. , said: “The method was already very good, but anything but routine.
Before Asymmetrex® developed the rapid stem cell count calculators officially introduced today, running its stem cell counting technology required 3-4 weeks of intensive and expensive cell culture procedures. However, the company used its earlier advances to define proprietary mathematical equations, which now power the company’s online fast counting calculators. With an online calculator, a user can routinely obtain the stem cell assay of cell preparations from any human tissue after culturing a small sample of cells for just 72 hours.
Asymmetrex® recently completed validation of its technology alongside the benchmark mouse SCID assay for estimating the dosage of human blood stem cells, which are widely used for approved stem cell transplantation therapies. The SCID mouse test was never adopted for routine use because it is expensive, requires 30–40 mice for a single count, takes over 16 weeks, and is unreliable. It also only works for blood stem cells. In contrast, Asymmetrex’s online rapid count calculators provide instant stem cell counts from user input of conventional cell data from just 72 hours of inexpensive cell culture. And calculators are available for stem cells of all human tissue types, not just blood stem cells.
There are custom calculators for different stem cell tissue sources and culture conditions. CEO Sherley says that “there are hundreds, if not thousands, of rapid stem cell count equations waiting to be processed by our software.” The company already offers generic calculators for five different types of stem cells commonly used in research, approved therapies, and many ongoing clinical stem cell trials. Asymmetrex® can also develop proprietary counting equations for proprietary stem cell sources and production conditions.
Previously, many companies that produced and used tissue stem cell products and treatments resigned themselves to not knowing their stem cell dose because no practical method was available to determine it. But dosing information was still needed to better ensure sufficient numbers of stem cells for effective treatment and to avoid wastage of rare stem cells due to unconscious overdosing.
Asymmetrex® has produced online educational forums and podcasts to reform ideas in stem cell science and stem cell medicine on the importance of careful stem cell dosing to accelerate research progress and stem cell therapy. According to Sherley, “Our company’s introduction of online rapid stem cell count calculators is the beginning of a reform of stem cell science and medicine.”
Asymmetrex®, LLC is a Massachusetts life sciences company focused on developing technologies to advance stem cell medicine. The company’s US and UK patent portfolio contains biotechnologies that solve the two main technical problems – specific stem cell quantification and stem cell expansion – that have prevented more effective use of stem cells from human adult tissues for regenerative medicine and drug development. . Asymmetrex commercializes Kinetic Stem Cell Counting (KSC), the first technology for determining the dose and quality of tissue stem cell preparations for use in stem cell transplantation medicine and preclinical drug evaluations. Asymmetrex® is a member company of the Advanced Regenerative Manufacturing Institute|BioFabUSA (ARMI) and the Massachusetts Biotechnology Council (MassBio). The company’s development of online calculators for rapid stem cell counting was supported by R&D grants from ARMI|BioFabUSA and the National Heart, Lung, and Blood Institute.
Share the article on social networks or by e-mail: